Lupin gets USFDA’s nod for Albendazole Tablets

12 Jun 2020 Evaluate

Lupin has received approval for its Albendazole Tablets USP, 200 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Albenza Tablets, 200 mg, of Impax Laboratories Inc.

Albendazole Tablets USP, 200 mg, are an anthelmintic drug indicated for treatment of Parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm and for Cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm. Albendazole Tablets USP (RLD: Albenza) had an annual sales of approximately $34 million in the U.S. (IQVIA MAT April 2020).

Lupin is an innovationled transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2089.65 -0.50 (-0.02%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×